Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Opthea Limited

Opthea is a clinical stage biopharmaceutical company committed to developing innovative therapies to help improve visual function in patients suffering with retinal diseases. Our first in class novel therapeutic called OPT-302, is a VEGF-C/D ‘trap’, to be used in combination with existing standard of care anti-VEGF-A therapies to improve vision in patients, many of whom respond sub-optimally or become refractory to existing treatments. Millions of people around the world suffer from impaired vision as a result of diabetes and old age. Our mission is to improve vision leading to a better quality of life. Enquiries can be directed to: info@opthea.com

COM:OPTHEA